Latest News about SNY
Recent news which mentions SNY
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
From Benzinga
Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation
January 26, 2024
From Benzinga
French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B
January 23, 2024
From Benzinga
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project
January 23, 2024
From Benzinga
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
January 22, 2024
From Benzinga
Sanofi's Olympic Endeavor: Leap Into Olympic Sponsorship Signals Cultural Transformation
January 10, 2024
From Benzinga
China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants
January 02, 2024
From Benzinga
Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January
December 29, 2023
From Benzinga
Why First Wave BioPharma Shares Are Skyrocketing Today
December 27, 2023
From Benzinga
From Benzinga
European Drugmaker Sanofi Ends Tusamitamab Ravtansine Lung Cancer Program After Disappointing Data
December 21, 2023
Tickers
SNY
From Benzinga
First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline
December 18, 2023
From Benzinga
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
December 17, 2023
Tags
ARCT
Market News
NASDAQ:HRMY,NASDAQ:MGNX,NYSE:PFE,NASDAQ:CPRX,NASDAQ:VYGR,NASDAQ:SNY,NASDAQ:ARCT
From InvestorPlace
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
December 17, 2023
From Motley Fool
French Drugmaker Sanofi Secures European Medicines Agency's Positive Opinion For Sleeping Sickness Treatment
December 15, 2023
Tickers
SNY
From Benzinga
3 Stocks to Buy Before 2024 That Can Set You Up For Life
December 14, 2023
From Motley Fool
French Pharma Giant Sanofi Drops Rare Disease Drug Pact As Federal Trade Commission Puts Antitrust Obstacle
December 12, 2023
Tickers
SNY
From Benzinga
Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company
December 07, 2023
From Benzinga
Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities
December 07, 2023
Tickers
SNY
From Benzinga
IGM Biosciences Increases Focus On Autoimmune Diseases, Stops All Blood Cancer-Related Studies
December 06, 2023
From Benzinga
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
December 06, 2023
From Benzinga
Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift
December 05, 2023
Tickers
SNY
From Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
December 01, 2023
From Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
November 30, 2023
From Motley Fool
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
November 27, 2023
From Benzinga
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
November 22, 2023
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.